Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 3
2001 13
2002 21
2003 39
2004 45
2005 59
2006 85
2007 90
2008 102
2009 87
2010 95
2011 87
2012 100
2013 115
2014 110
2015 91
2016 88
2017 84
2018 86
2019 55
2020 4
Text availability
Article attribute
Article type
Publication date

Search Results

1,240 results
Results by year
Filters applied: . Clear all
Page 1
Psoriasis.
Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, Mehta NN, Finlay AY, Gottlieb AB. Greb JE, et al. Nat Rev Dis Primers. 2016 Nov 24;2:16082. doi: 10.1038/nrdp.2016.82. Nat Rev Dis Primers. 2016. PMID: 27883001 Review.
Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up.
Kurizky PS, Galvão LO, Martins GA. Kurizky PS, et al. An Bras Dermatol. 2019 Oct 17;94(4):483-484. doi: 10.1590/abd1806-4841.20198358. eCollection 2019. An Bras Dermatol. 2019. PMID: 31644629 Free PMC article. No abstract available.
Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M, Osório F, Morais P, Torres T, Magina S, Chimenti S, Costanzo A. Papoutsaki M, et al. BioDrugs. 2013 Jan;27 Suppl 1:13-23. doi: 10.1007/BF03325638. BioDrugs. 2013. PMID: 23990278 Review.
Infliximab for psoriasis and psoriatic arthritis.
Antoni C, Manger B. Antoni C, et al. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S122-5. Clin Exp Rheumatol. 2002. PMID: 12463461
Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis.
Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Muñoz-Aceituno E, Reolid A, Saiz-Rodríguez M, Belmonte C, Román M, Ochoa D, Talegón M, Cabaleiro T, Daudén E, Abad-Santos F. Ovejero-Benito MC, et al. Pharmacogenomics. 2018 Jan;19(1):7-16. doi: 10.2217/pgs-2017-0143. Epub 2017 Dec 1. Pharmacogenomics. 2018. PMID: 29192552 Clinical Trial.
Drug survival of biologic treatments in psoriasis: a systematic review.
No DJ, Inkeles MS, Amin M, Wu JJ. No DJ, et al. J Dermatolog Treat. 2018 Aug;29(5):460-466. doi: 10.1080/09546634.2017.1398393. Epub 2017 Nov 10. J Dermatolog Treat. 2018. PMID: 29076754 Review.
Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial.
Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE; EXPRESS study investigators. Reich K, et al. Lancet. 2005 Oct 15-21;366(9494):1367-74. doi: 10.1016/S0140-6736(05)67566-6. Lancet. 2005. PMID: 16226614 Clinical Trial.
1,240 results
Jump to page
Feedback